OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
November 08, 2022
Focus is on cash: who’s got it, who doesn’t, and what will it mean?
October 11, 2022
Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.
As fundamentals improve, potential rate plateau could ignite growth.
September 14, 2022
Rotz discusses a report he co-authored for PwC about how life sciences companies perform on the S&P 500.
September 09, 2022
Our latest metrics tally across seven business-key measures uncovers some familiar players pacing the field in delivering shareholder value and getting the most from their investments.
Biotech stocks and the indexes have staged an impressive recovery.
September 08, 2022
Barnes discusses alternative reimbursement plans for expensive, one-off therapies.
August 10, 2022
A review of pharma and biotech equity market, IPO, and M&A trends and outputs through the first half of 2022—and implications for the future as disruptions continue to have an impact.
A look at the driving factors behind renewed optimism.
July 20, 2022
A recent analysis of the biotech market shows promising signs.